PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Second-Year RSV Admissions Draw Far More Steroids and Antibiotics Despite Milder Course

respiratory syncytial virusRSVbronchiolitispediatricantibioticssystemic corticosteroidsantimicrobial stewardshipretrospective cohortsecond year of lifeimmunoprophylaxis Infectious Disease / Antimicrobials
Also in Pediatrics

Background Information

Are second-year RSV hospitalizations less severe yet over-treated?

Respiratory syncytial virus (RSV) is a major cause of hospitalization in children, and this study highlights differences in disease characteristics between the first and second years of life. Second-year RSV hospitalizations showed higher use of corticosteroids (53.5% vs. 23.2%) and antibiotics (63.4% vs. 45.9%) compared to first-year, but lower pediatric intensive care unit (PICU) admissions (4.6% vs. 7.0%). This study emphasizes the need for targeted strategies for children in their second year of life, due to increased medication use despite less severe outcomes. Second-year RSV hospitalization cases use more antibiotics and corticosteroids despite lower PICU admissions.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Armoni Domany K, Golan-Tripto I, Burrack N, Masarweh K, Gur M, Rochman M, Be'er M, Prais D, Mor M, Weinberger Opek M, Nasrallah E, Megged O, Shatzman Steuerman R, Stein M, Steinberg Z, Shehadeh S, Glatman-Freedman A, Tasher D

Citation: Armoni Domany K, Golan-Tripto I, Burrack N, et al. RSV Disease Among Hospitalized Children: Second vs. First Year of Life Multicenter Study. Influenza and other respiratory viruses. 2026;20(11). doi:10.1111/irv.70338

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.